4-氰基-2(1H)-吡啶酮 | 94805-51-3

• 物质功能分类: 医药中间体 - 杂环化合物 - 吡啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 4-氰基-2(1H)-吡啶酮
• 中文别名: 2-羟基异烟腈
• 英文名称: 2-hydroxyisonicotinonitrile
• 英文别名: 2-oxo-1H-pyridine-4-carbonitrile
• CAS: 94805-51-3
• 化学式: C₆H₄N₂O
• mdl: MFCD04037920
• 分子量: 120.111
• InChiKey: QCOIIYBOBZFBJE-UHFFFAOYSA-N

物化性质

• 熔点：
  285-288
• 沸点：
  102-104°C/6.8mm
• 闪点：
  107 °C

计算性质

• 辛醇/水分配系数(LogP)：
  -0.4
• 重原子数：
  9
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  52.9
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 危险品标志：
  Xi
• 安全说明：
  S26,S37
• 危险类别码：
  R36/37/38
• 海关编码：
  2933399090
• 危险性防范说明：
  P261,P280,P305+P351+P338
• 危险性描述：
  H302+H312+H332,H315,H319,H335
• 储存条件：
  室温下应存放在干燥密封的环境中。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 4-Cyano-2(1H)-pyridinone
Synonyms: 2-Hydroxyisonicotinonitrile; 4-Cyano-2-hydroxypyridine; 2-oxo-1,2-dihydropyridine-4-carbonitrile

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H302: Harmful if swallowed
H315: Causes skin irritation
H318: Causes serious eye damage
H335: May cause respiratory irritation
P261: Avoid breathing dust/fume/gas/mist/vapours/spray
P280: Wear protective gloves/protective clothing/eye protection/face protection
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing

---

Section 3. Composition/information on ingredients.
Ingredient name: 4-Cyano-2(1H)-pyridinone
CAS number: 94805-51-3

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Not specified
Appearance:
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C6H4N2O
Molecular weight: 120.1

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  4-氰基-2(1H)-吡啶酮 在 吡啶 、 copper(I) oxide 、 N-碘代丁二酰亚胺 、 三甲基氯硅烷 、 盐酸羟胺 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 N,N-二异丙基乙胺 、 sodium iodide 作用下， 以 乙醇 、 二甲基亚砜 、 N,N-二甲基甲酰胺 、 乙腈 为溶剂， 反应 11.0h， 生成 2-amino-2-(5-(5-(3,4-diethoxyphenyl)-1,2,4-oxadiazol-3-yl)furo[2,3-b]pyridin-2-yl)propane-1,3-diol
  参考文献：
  名称：

  [EN] ORGANIC COMPOUNDS
  [FR] COMPOSÉS ORGANIQUES

  摘要：

  揭示了新型苯并呋喃衍生物。这些衍生物具有S1P1受体活性和/或疾病修饰活性，并可用于治疗与动物和/或人类的免疫、血管和神经系统相关的疾病或症状。

  公开号：

  WO2014063199A1
• 作为产物：
  描述：

  4-氰基吡啶 在 sodium hydroxide 作用下， 以 水 为溶剂， 反应 44.0h， 生成 4-氰基-2(1H)-吡啶酮
  参考文献：
  名称：

  PROCESS FOR PRODUCTION OF 2-HYDROXY-4-SUBSTITUTED PYRIDINES

  摘要：

  公开号：

  EP1801102B1

文献信息

• BIARYL PDE4 INHIBITORS FOR TREATING PULMONARY AND CARDIOVASCULAR DISORDERS
  申请人：Singh Jasbir

  公开号：US20090136473A1

  公开（公告）日：2009-05-28

  The present invention relates to a genus of biaryl compounds containing at least one further ring. The compounds are PDE4 inhibitors useful for the treatment and prevention of stroke, myocardial infarct and cardiovascular inflammatory diseases and disorders. The compounds have general formula Ia, Ib, Ic or Id: A particular embodiment is

  本发明涉及一类含有至少一个进一步环的联苯化合物的属。这些化合物是PDE4抑制剂，用于治疗和预防中风、心肌梗死和心血管炎症性疾病和紊乱。这些化合物具有一般式Ia、Ib、Ic或Id： 一个特定的实施例是
• [EN] P2X3 AND/OR P2X2/3 COMPOUNDS AND METHODS<br/>[FR] COMPOSÉS DE P2X3 ET/OU P2X2/3 ET PROCÉDÉS
  申请人：ASANA BIOSCIENCES LLC

  公开号：WO2015095128A1

  公开（公告）日：2015-06-25

  The present application provides novel compounds and methods for preparing and using these compounds. In one embodiment, the compounds are of the structure of formula (I), wherein R1-R4 are defined herein. In a further embodiment, these compounds are useful in method for regulating one or both of the P2X3 or P2X2/3 receptors. In another embodiment, these compounds are useful for treating pain in patients by administering one or more of the compounds to a patient.

  本申请提供了新颖的化合物以及制备和使用这些化合物的方法。在一个实施例中，这些化合物具有如下式（I）的结构，其中R1-R4在此处被定义。在另一个实施例中，这些化合物在调节P2X3或P2X2/3受体中的一个或两个的方法中是有用的。在另一个实施例中，这些化合物通过向患者施用一个或多个化合物来治疗患者的疼痛是有用的。
• Boron-Containing Small Molecules as Anti-Inflammatory Agents
  申请人：ANACOR PHARMACEUTICALS, INC.

  公开号：US20150291629A1

  公开（公告）日：2015-10-15

  Compounds and methods of treating anti-inflammatory conditions are disclosed.

  化合物和治疗抗炎症状况的方法被披露。
• Design, synthesis, and biological evaluation of a novel series of peripheral-selective noradrenaline reuptake inhibitors – Part 3
  作者：Tomoya Yukawa、Yoshihisa Nakada、Nobuki Sakauchi、Taku Kamei、Masami Yamada、Yusuke Ohba、Ikuo Fujimori、Hiroyuki Ueno、Maiko Takiguchi、Masako Kuno、Izumi Kamo、Hideyuki Nakagawa、Yasushi Fujioka、Tomoko Igari、Yuji Ishichi、Tetsuya Tsukamoto

  DOI：10.1016/j.bmc.2016.06.014

  日期：2016.8

  noradrenaline reuptake is a novel mechanism for the treatment of stress urinary incontinence to overcome adverse effects associated with central action. Here, we describe our medicinal chemistry approach to discover a novel series of highly potent, peripheral-selective, and orally available noradrenaline reuptake inhibitors with a low multidrug resistance protein 1 (MDR1) efflux ratio by cyclization of

  去甲肾上腺素再摄取的外周选择性抑制是一种新的机制，用于治疗压力性尿失禁，以克服与中枢作用相关的不良反应。在这里，我们描述了我们的药物化学方法，通过酰胺部分的环化和酸性引入，发现了一系列新型的高效，外周选择性和口服可用的去甲肾上腺素再摄取抑制剂，具有低多药耐药性蛋白1（MDR1）外排比。团体。我们观察到，MDR1外排率与酸性部分的p K a值相关。所得化合物9表现出有利的PK曲线，这可能是由于分子内氢键的作用，该氢键由其单晶结构支撑。化合物9，1 - [（6-小号，7 - [R）-7-（4-氯-3-氟苯基）-1,4-氧氮杂环庚-6-基]甲基} -2-氧代-1,2-二氢吡啶-3-通过口服给药在大鼠的测试剂量下表现出外周NET选择性抑制作用的β-羧酸盐酸盐以剂量依赖的方式增加了尿道抵抗性。
• Synthesis and evaluation of potent and selective MGL inhibitors as a glaucoma treatment
  作者：Shakiru O. Alapafuja、Michael S. Malamas、Vidyanand Shukla、Alexander Zvonok、Sally Miller、Laura Daily、Girija Rajarshi、Christina Yume Miyabe、Honrao Chandrashekhar、JodiAnne Wood、Sergiy Tyukhtenko、Alex Straiker、Alexandros Makriyannis

  DOI：10.1016/j.bmc.2018.11.003

  日期：2019.1

  Monoacylglycerol lipase (MGL) inhibition provides a potential treatment approach to glaucoma through the regulation of ocular 2-arachidonoylglycerol (2-AG) levels and the activation of CB1 receptors. Herein, we report the discovery of new series of carbamates as highly potent and selective MGL inhibitors. The new inhibitors showed potent nanomolar inhibitory activity against recombinant human and purified

  单酰基甘油脂肪酶 (MGL) 抑制通过调节眼部 2-花生四烯酸甘油 (2-AG) 水平和激活 CB1 受体，为青光眼提供了一种潜在的治疗方法。在此，我们报告发现了新系列的氨基甲酸酯作为高效和选择性的 MGL 抑制剂。新抑制剂对重组人和纯化的大鼠 MGL 显示出有效的纳摩尔抑制活性，对丝氨酸水解酶 FAAH 和 ABHD6 具有选择性（> 1000 倍），并且对大麻素受体 CB1 和 CB2 没有任何亲和力。基于蛋白质的1 H NMR 实验表明抑制剂2与 MGL 迅速形成共价加合物，停留时间约为 6 小时。通过修改配体的大小（长度和体积）来利用这种相互转化过程“内在可逆性”来生成具有“可调”加合物停留时间 (τ) 的类似物。在血压正常的小鼠模型中对抑制剂2进行评估，以评估眼内压 (IOP)，这可能导致青光眼，这是导致失明的主要原因。发现抑制剂2在单次眼部应用后至少 12 小时内以持续方式将眼压降低约